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(Affiliations continued on next page)SUMMARYWe collated data from 157 unpublished cases of pediatric high-grade glioma and diffuse intrinsic pontine
glioma and 20 publicly available datasets in an integrated analysis of >1,000 cases. We identified co-segre-
gating mutations in histone-mutant subgroups including loss of FBXW7 in H3.3G34R/V, TOP3A rearrange-
ments in H3.3K27M, and BCOR mutations in H3.1K27M. Histone wild-type subgroups are refined by the
presence of key oncogenic events or methylation profiles more closely resembling lower-grade tumors.
Genomic aberrations increase with age, highlighting the infant population as biologically and clinically
distinct. Uncommon pathway dysregulation is seen in small subsets of tumors, further defining themolecular
diversity of the disease, opening up avenues for biological study and providing a basis for functionally
defined future treatment stratification.INTRODUCTION
Pediatric glioblastoma (pGBM) and diffuse intrinsic pontine gli-
oma (DIPG) are high-grade glial tumors of children with a me-Significance
High-grade and diffuse intrinsic pontine glioma in children are
cancers. An integrated genomic, epigenomic and transcriptom
ments of the CNS defines robust clinicopathological and mole
classification schemes begin to recognize the diversity of this
for meaningful further subcategorization and identify subgrou
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This is an open access article under the CC BY license (http://creativedian overall survival of 9–15 months, a figure that has remained
unmoved for decades (Jones et al., 2012). Although relatively
rare in this age group (1.78 per 100,000 population), taken
together, gliomas are nonetheless the most common malignantrare, incurable brain tumors with differing biology to adult
ic analysis of >1,000 cases across all anatomical compart-
cular subgroups with distinct biological drivers. As modern
disease in the pediatric population, we provide a framework
p-restricted therapeutic targets.
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http://dx.doi.org/10.1016/j.ccell.2017.08.017brain tumors in children, and represent the greatest cause of
cancer-related deaths under the age of 19 years (Ostrom
et al., 2015). Unlike histologically similar lesions in adults, which
tend to be restricted to the cerebral hemispheres, diffuse high-
grade gliomas in childhood (pHGG) can occur throughout the
CNS, with around half occurring in midline locations, in partic-
ular the thalamus and the pons (Jones and Baker, 2014), where
the lack of available surgical options confers an especially poor
prognosis (Kramm et al., 2011). Numerous clinical trials of
chemotherapeutics and targeted agents extrapolated from
adult GBM studies have failed to show a survival benefit, and
more rationally derived approaches based upon an understand-
ing of the childhood diseases are urgently needed (Jones
et al., 2016).
It has become increasingly apparent that pHGG differ from
their adult counterparts, with molecular profiling studies carriedout over the last 6–7 years having incrementally identified key
genetic and epigenetic differences in pHGG associated with
distinct ages of onset, anatomical distribution, clinical outcome,
and histopathological and radiological features (Jones and
Baker, 2014; Sturm et al., 2014). In particular, the identification
of unique recurrent mutations in genes encoding histones H3.3
and H3.1 (Schwartzentruber et al., 2012; Wu et al., 2012) have
demonstrated the distinctiveness of the pediatric disease, with
the G34R/V and K27M variants appearing to represent different
clinicopathological and biological subgroups. This has been
recognized by the World Health Organization (WHO) classifica-
tion of CNS tumors, with the latest version including the novel en-
tity, diffuse midline glioma with H3K27 mutation (Louis et al.,
2016). Further refinements incorporating other clearly delineated
subsets of the disease in future iterations appear likely andmight
prove clinically useful.Cancer Cell 32, 520–537, October 9, 2017 521
In addition to these uniquely defining histone mutations,
detailed molecular profiling has served to identify numerous
targets for therapeutic interventions. These include known onco-
genes in adult glioma and other tumors with an elevated fre-
quency in the childhood setting (e.g., PDGFRA) (Paugh et al.,
2013; Puget et al., 2012) or certain rare histological variants
(e.g., BRAF V600E) (Nicolaides et al., 2011; Schiffman et al.,
2010), as well as others seemingly unique to DIPG (e.g.,
ACVR1) (Buczkowicz et al., 2014; Fontebasso et al., 2014; Taylor
et al., 2014a; Wu et al., 2014). Future trials will need to exploit
these targets, but also incorporate innovative designs that allow
for selection of the patient populations within the wide spectrum
of disease who are most likely to benefit from any novel agent
(Jones et al., 2016).
Despite these advances, driven by the efforts of several inter-
national collaborative groups to collect and profile these rare tu-
mors, individual publications remain necessarily modestly sized,
involving a range of different platforms and analytical tech-
niques. This leaves certain subgroups poorly represented across
studies, widely differing individual gene frequencies in different
cohorts, and an inability to draw robust conclusions across the
whole spectrum of the disease. We have gathered together pub-
licly available data, supplemented with 157 new cases, in order
to provide a statistically robust, manually annotated resource
cohort of >1,000 such tumors for interrogation.
RESULTS
Sample Cohort
In total, we obtained data from clinically annotated high-grade
glioma (WHO, 2007, grade III or IV) or DIPG (radiologically diag-
nosed, grades II–IV) in 1,067 unique cases (Figure S1A). These
were predominantly from children but also included young
adults, in order to capture more H3F3A G34R/V mutations, as
well as to explore an otherwise under-studied population. There
was a median age at diagnosis of 9.8 years, and 982 cases aged
21 years or younger (Table S1). These included 910 taken from
20 published series (Barrow et al., 2011; Bax et al., 2010; Bucz-
kowicz et al., 2014; Carvalho et al., 2014; Castel et al., 2015;
Fontebasso et al., 2013, 2014; Grasso et al., 2015; International
Cancer Genome Consortium PedBrain Tumor Project, 2016;
Khuong-Quang et al., 2012; Korshunov et al., 2015; Paugh
et al., 2010, 2011; Puget et al., 2012; Schwartzentruber et al.,
2012; Sturm et al., 2012; Taylor et al., 2014a; Wu et al., 2012;
Wu et al., 2014; Zarghooni et al., 2010) and 157 unpublished
cases. The vast majority of samples were obtained pre-treat-
ment (biopsy or resection, n = 913), as opposed to post-therapy
(relapse or autopsy, n = 146). Samples were classified as occur-
ringwithin the cerebral hemispheres (n = 482), brainstem (n = 323
in pons, of which 322 were DIPG; three additional cases were in
the midbrain and one in the medulla) or other non-brainstem
midline locations (n = 224, predominantly thalamus, but also
cerebellum, spinal cord, ventricles, and others; referred to as
‘‘midline’’ for simplicity throughout) (Figure 1A). There was a sig-
nificant association of anatomical location with age of diagnosis,
with medians of 13.0 years for hemispheric, 10.0 years for
midline, and 6.5 years for DIPG, respectively (p < 0.0001,
ANOVA; all pairwise comparisons adjusted p < 0.0001, t test)
(Figure 1B), in addition to clinical outcome, with a median overall522 Cancer Cell 32, 520–537, October 9, 2017survival of 18.0 months for hemispheric tumors (2 year overall
survival 32%), 13.5 months for midline (2 year overall survival
21.4%), and 10.8 months for DIPG (2 year overall survival
5.2%; p < 0.0001 for all pairwise comparisons, log rank test) (Fig-
ure 1C). Children 3 years of age and younger had a markedly
improved clinical outcome (p = 0.0028, log rank test), although
this benefit was largely restricted to children 1 year and under
(n = 40, 2 year survival 61%, p < 0.0001, log rank test), with
this association significant in all anatomical locations (p =
0.0402, hemispheric; p < 0.0001, midline; p = 0.00286, pons,
log rank test). There were, however, proportionally fewer midline
and pontine tumors in <1-year-olds compared with 1- to 3-year-
olds (12/40, 30.0% versus 46/85, 45.9%, p = 0.0131 Fisher’s
exact test) (Figures S1B and S1C).
Molecular Subgrouping
Hotspot mutation data for the genes encoding histone H3 were
available or newly generated for 903 cases. At minimum, this
included Sanger sequencing for H3F3A (H3.3) and HIST1H3B
(H3.1); however, the absence of wider screening or next-gener-
ation sequencing data for 310 cases annotated as H3 wild-type
(WT) means we cannot rule out rare variants in other H3.1 or
H3.2 genes in those cases. In total, the cohort comprised 67
H3.3G34R/V (n = 63 G34R, n = 4 G34V), 316 H3.3K27M, 66
H3.1/3.2K27M (n = 62 HIST1H3B, n = 2 HIST1H3C, n = 2
HIST2H3C), and 454 WT. There were profound distinctions in
anatomical location (p < 0.0001, Fisher’s exact test) (Figure 1D),
age at diagnosis (p < 0.0001, ANOVA; all pairwise comparisons
adjusted p < 0.0001, t test) (Figure 1E), and overall survival
(p < 0.0001, log rank test) (Figure 1F). H3.3G34R/V tumors
were almost entirely restricted to the cerebral hemispheres (ac-
counting for 16.2% total in this location, particularly parietal
and temporal lobes), were found predominantly in adolescents
and young adults (median 15.0 years), and had a longer
overall survival compared with other H3 mutant groups (me-
dian 18.0 months, 2 year overall survival 27.3%, p < 0.0001
versus H3.3K27M, p = 0.00209 versus H3.1H27M, log rank
test). H3.3K27M were spread throughout the midline and
pons, where they account for 63.0% DIPG and 59.7% non-
brainstem midline tumors. In all locations (including ten cases
reported to present in the cortex), these mutations conferred
a significantly shorter time to death from disease (overall me-
dian 11 months, 2 year overall survival 4.7%) (Figures S1D–
S1F). H3.1/3.2K27M were highly specific to the pons (21.4%
total) where they represent a younger age group (median 5.0
years) with a significantly longer overall survival (median
15.0 months) than H3.3K27M (p = 0.00017, log rank test)
(Figure S1F). In multivariate analysis incorporating the histone
mutations alongside age, WHO grade, and gender, K27M mu-
tations in both H3.3 and H3.1 are independently associated
with shorter survival (p < 0.0001, Cox proportional haz-
ards model).
BRAF V600E status was available for 535 cases, with mutant
cases (n = 32, 6.0%) present only in midline and hemispheric
locations, and conferring a significantly improved prognosis
(2 year survival 67%, p < 0.0001, log rank test) (Figures S1G–
S1I). There was additional annotation for IDH1 R132 mutation
status in 640 cases (n = 40, 6.25%), representing a forebrain-
restricted, significantly older group of patients (median 17.0
Figure 1. Clinicopathological and Molecular Subgroups of pHGG/DIPG
(A) Anatomical location of all high-grade glioma cases included in this study, taken from original publications (n = 1,033). Left, sagittal section showing internal
structures; right, external view highlighting cerebral lobes. Hemispheric, dark red; non-brainstem midline structures, red; pons, pink. Radius of circle is pro-
portional to the number of cases. Lighter shaded circles represent a non-specific designation of hemispheric, midline, or brainstem.
(B) Boxplot showing age at diagnosis of included cases, separated by anatomical location (n = 1,011). The thick line within the box is the median, the lower and
upper limits of the boxes represent the first and third quartiles, and the whiskers 1.53 the interquartile range. ***Adjusted p < 0.0001 for all pairwise comparisons,
t test.
(C) Kaplan-Meier plot of overall survival of cases separated by anatomical location, p value calculated by the log rank test (n = 811).
(D) Anatomical location of all cases separated by histone mutation (top, n = 441) and histone WT (bottom, n = 314). Left, sagittal section showing internal
structures; right, external view highlighting cerebral lobes. Blue, H3.3G34R/V; green, H3.3K27M; dark green, H3.1K27M. Radius of circle is proportional to the
number of cases. Lighter shaded circles represent a non-specific designation of hemispheric, midline, or brainstem.
(E) Boxplot showing age at diagnosis of included cases, separated by histone mutation (n = 753). The thick line within the box is the median, the lower and upper
limits of the boxes represent the first and third quartiles, and the whiskers 1.53 the interquartile range. ***Adjusted p < 0.0001 for all pairwise comparisons, t test.
(F) Kaplan-Meier plot of overall survival of cases separated by histone mutation, p value calculated by the log rank test (n = 693). See also Figure S1 and Table S1.
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years, p < 0.0001, t test) with longer overall survival (2 year sur-
vival 59%, p < 0.0001, log rank test) (Figures S1J–S1L).
For 441 cases, Illumina 450k methylation BeadArray data was
available, which provides robust classification into clinically
meaningful epigenetic subgroups marked by recurrent genetic
alterations (Korshunov et al., 2015, 2017). We used the Heidel-
berg brain tumor classifier to assign tumors into following sub-
groups: H3G34R/V (n = 51), H3K27M (n = 119), HGG WT (n =
156), IDH1 (n = 36), low-grade glioma (LGG)-like (n = 27), pleo-
morphic xanthoastrocytoma (PXA)-like (n = 43), and ‘‘other’’
(n = 9) (Figure S2A), visualized by hierarchical clustering (Fig-
ure 2A) (Table S2). As reported previously, these subgroups
have profound differences in anatomical location (Figure 2B),
age at diagnosis (p < 0.00001 ANOVA) (Figure 2C), and overall
survival (p < 0.0001, log rank test) (Figure 2D), with LGG-like
group representing a younger cohort (median 4.0 years, 10/16
infant cases under 1 year, p < 0.0001 Fisher’s exact test) with
excellent prognosis (2 year survival 74%, p < 0.0001 versus
WT, log rank test), while the PXA-like group are enriched for
BRAF V600E mutations (19/34, 56%) and carry an intermediate
risk (median 38 months, 2 year survival 56%, p = 0.00423 versus
WT, log rank test). After removing the PXA- and LGG-like groups,
the remaining histone H3/IDH1 WT tumors had a 2 year survival
of 23.5% (median overall survival 17.2months).MGMT promoter
methylation was significantly enriched in the H3G34R/V (65.1%,
globally hypomethylated) and IDH1 (78.1%, globally hyperme-
thylated) groups, and largely absent from H3K27M tumors
(4.5%, all tests versus rest, p < 0.0001 Fisher’s exact test) (Fig-
ure S2B). Total methylation was lowest in H3G34R/V (median
beta value 0.452), and highest in the IDH subgroup (median
beta value 0.520), as reported previously (Sturm et al., 2012);
however it was also found to be significantly elevated in
PXA-like tumors (median beta value 0.501, p < 0.0001 t test)
(Figure S2C).
DNA Copy Number
High-quality DNA copy-number profiles were obtained from 834
unique cases of pHGG/DIPG, taken from BAC and oligonucleo-
tide arrays (n = 112), SNP arrays (n = 128), 450k methylation ar-
rays (n = 428), and whole-genome or exome sequencing (n =
325) (Table S3). Clustering on the basis of segmented log2 ratios
highlighted some of the defining chromosomal features of the
pediatric disease, including recurrent gains of chromosome 1q,
and losses of chromosomes 13q and 14q (Figure 3A). There
are also a significant proportion of tumors (n = 147, 17.6%)
with few if any DNA copy-number changes, with no bias toward
lower-resolution platforms (p = 0.134, Fisher’s exact test), andFigure 2. Methylation-based Subclassification of pHGG/DIPG
(A) Unsupervised hierarchical clustering and heatmap representation of b values fo
low). Samples are arranged in columns clustered bymost variable 1,381 classifier
annotations are provided as bars according to the included key.
(B) Anatomical location of methylation-defined PXA-like (n = 43) and LGG-like (n =
highlighting cerebral lobes. Dark gold, PXA-like; tan, LGG-like. Radius of circle is
specific designation of hemispheric, midline, or brainstem.
(C) Boxplot showing age at diagnosis of included cases, separated by simplified
lower and upper limits of the boxes represent the first and third quartiles, and the
pairwise comparisons, t test; **adjusted p < 0.01 for LGG-like versus WT, t test.
(D) Kaplan-Meier plot of overall survival of cases separated by simplifiedmethylati
and Table S2.the presence of other molecular markers obviating concerns of
a substantial normal tissue contamination. These cases were
found throughout the CNS, were younger at diagnosis (7.0
versus 10.3 years, p < 0.0001, t test) and had a longer overall sur-
vival (median 18.0 versus 14.0 months, p = 0.0107 log rank test)
(Figure S3A). Common large-scale chromosomal alterations with
prognostic significance included loss of 17p (n = 156), which tar-
gets TP53 at 17p13.1 and confers a shorter overall survival in tu-
mors of all locations and all subgroups (Figure S3B), and gains of
9q (n = 108), more broadly encompassing a region of structural
rearrangement on 9q34 in medulloblastoma (Northcott et al.,
2014), and correlating with shorter overall survival in multiple
pHGG/DIPG subgroups (Figure S3C).
We used GISTIC (genomic identification of significant targets
in cancer) in order to determine subgroup-specific copy-number
drivers based on focality, amplitude, and recurrence of alter-
ations. The most common focal events were the previously
described high-level amplifications (Figure 3B) at 4q12
(PDGFRA/KIT/KDR, n = 77), 2p24.3 (MYCN/ID2, n = 42), chro-
mosome 7 (7p11.2 (EGFR, n = 32), 7q21.2 (CDK6, n = 14), and
7q31.2 (MET, n = 19)) (Figures S3D–S3F), as well as focal
deletions (Figure 3C) at 9p21.3 (CDKN2A/CDKN2B, n = 102)
(Figure S3G). Amplifications conferred a shorter overall
survival, and CDKN2A/CDKN2B deletion a better prognosis,
either across the whole cohort or selected subgroups (Fig-
ures S3B–S3G). In addition, the aggregated data identified
less-frequent alterations, recurrent acrossmultiple studies, iden-
tifying pHGG/DIPG candidates includingNFIB (nuclear factor I B,
9p23-p22.3, n = 4), GAB2 (GRB2-associated binding protein 2,
11q14.1, n = 4), SMARCE1 (SWI/SNF related, matrix associated,
actin dependent regulator of chromatin, subfamily e, member 1,
17q21.2, n = 4), and others (Figures 3B and 3C).
Subgroup-Specific Alterations
When IDH1-mutant tumors were removed and the cohort
restricted to those cases for which histone H3 status was avail-
able, we were able to investigate subgroup-specific DNA copy-
number changes in 705 pHGG/DIPG (Figure 4A). Applying
GISTIC within these case sets revealed specific focal events
enriched within individual subgroups, including AKT1 amplifica-
tions in H3.3G34R/V, MYC and CCND2 amplification in
H3.3K27M, andMYCN/ID2, MDM4/PIK3C2B, and KRAS ampli-
fication in H3WT (Figure 4B) (Table S4). These latter events were
generally restricted to hemispheric tumors, while MYCN/ID2
were enriched in H3 WT DIPG (Figure S4A). H3.1K27M tumors
generally lacked amplifications/deletions, but were instead char-
acterized by frequent gains of 1q and the whole of chromosomer 441 samples profiled on the Illumina 450k BeadArray platform (red, high; blue,
probes. Age at diagnosis is provided below. Clinicopathological and molecular
27) cases. Left, sagittal section showing internal structures; right, external view
proportional to the number of cases. Lighter shaded circles represent a non-
methylation subclass (n = 440). The thick line within the box is the median, the
whiskers 1.53 the interquartile range. ***Adjusted p < 0.0001 for all H3 G34R/V
on subclass, p value calculated by the log rank test (n = 307). See also Figure S2
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2, and the loss of 16q (Figure 4C). PXA-like tumors had frequent
CDKN2A/B deletions and a unique loss at 1q, associated with
shorter overall survival within this group (Figure S4B).
Whole-arm losses were also enriched in H3.3G34R/V tumors,
specifically 3q, 4q, 5q, and 18q, where smallest regions of over-
lap were in some instances able to narrow the common region to
a handful of candidate genes (Figure S4C). On chromosome 4q
this appeared to target FBXW7 at 4q31.3, also aligning with the
GISTIC data (Figure 5A). Across three independent platforms,
gene expression over the whole arm was significantly lower
when 4q was lost (Agilent, p = 0.00231; Affymetrix, p =
0.000102; RNA sequencing (RNA-seq), p = 0.0398; Wilcoxon
signed-rank test) (Figure S5A). (Table S5). There were also four
patients with three different somatic coding mutations identified
(below), two truncating and one missense, three of which were
in hemispheric tumors, and two with H3F3A G34R (Figure 5B).
In cases with 4q loss, median FBXW7 gene expression was
reduced comparedwith thosewith normal copy number (Agilent,
p = 0.029; Affymetrix, p = 0.015; RNA-seq, p = 0.4; Mann-Whit-
ney U test) (Figure 5C).
Within H3.3K27M tumors, we identified a recurrent amplifica-
tion at 17p11.2 (n = 17; 170 kb to 11.96Mb), across multiple plat-
forms and significantly enriched in DIPGs, which appears to
target TOP3A within these tumors (Figure 5D). Where available
(n = 6) (Figure S5B), whole-genome sequencing data reveals
this occurs via complex intra- and inter-chromosomal rearrange-
ments (Figure 5E) leading to increased mRNA expression of
TOP3A in amplified versus non-amplified cases in Agilent
(n = 1), and Affymetrix and RNA-seq (p = 0.011 and p = 0.016,
respectively, Mann-Whitney U test) data (Figure 5F) (Table S5).
In an integrated dataset, TOP3A was the most differentially ex-
pressed gene in the region in amplified cases (adjusted p =
0.00856 Mann-Whitney U test). We further identified a single so-
matic missense mutation (C658Y) in an additional case of DIPG,
and, taken together, TOP3A alterations were mutually exclusive
with ATRX deletion/mutations found in H3.3K27M DIPG (0/13).
Whole-Genome and Exome Sequencing
Out of 372 sequenced cases (n = 118 whole genome, n = 247
exome, 7 both), we were able to retrieve raw data from 351 for
integration of somatic variant calling (Table S6) and DNA copy-
number changes. Of these, RNA-seq data was available for 47,
allowing for candidate fusion gene nomination in 150 cases
(RNA-seq or whole-genome sequencing restricted to high-
confidence nominations in relevant pathway-associated genes,
Table S6). Taking a conservative approach to variant calling
given the disparate sequencing coverage (median 883, range
16–2953), capture platforms, and availability of germline data,
we report a median number of somatic single nucleotide variants
(SNVs) and insertion/deletions (InDels) of 12, with 97% cases in
the range 0–305. DNA copy neutral cases had significantly fewer
somatic mutations (median 8.37 versus 21.32 SNVs/InDels perFigure 3. DNA Copy-Number Aberrations in pHGG/DIPG
(A) Heatmap representation of segmented DNA copy number for 834 pHGG/DIP
cation; red, gain; dark blue, deletion; blue, loss). Samples are arranged in colum
provided below. Clinicopathological and molecular annotations are provided as
(B and C) Barplot of all recurrent focal amplifications (B) and deletions (C) acro
anatomical location and histone mutation. See also Figure S3 and Table S3.case), with those copy neutral cases also having no detectable
mutations falling into the youngest age group (median = 3.9
years). There was only a modestly elevated mutation rate be-
tween samples taken post- compared with pre-treatment (1.5-
fold, p = 0.056, t test) (Figure S6A). However, 11 cases had
a vastly increased mutational burden, described as a hyper-
mutator phenotype (median 13,735 SNVs/InDels, range 852–
38,250), with distinctive mutational spectra from non-hypermu-
tated pHGG/DIPG (Shlien et al., 2015), including three cases
with plausible somatic activating POLE mutations (Figure S6B).
IDH1-mutant cases were again excluded (n = 14), with genetic
profiles identical to that described in adults for astrocytic tumors
(13/14 TP53, 7/14 ATRXmutations), and oligodendroglial tumors
(1p19q co-deletion, TERT promoter, CIC, FUBP1 mutations)
entirely absent (Figure S6C). We were thus left with an integrated
dataset of 326 pHGG/DIPG, providing robust annotation of the
most frequently altered genes across histone H3 subgroups
and anatomical locations (Figure 6A). As well as known associa-
tions such as hemispheric H3.3G34R/V and TP53/ATRX (18/20,
90%; p = 0.0001), midline H3.3K27M and FGFR1 (8/39, 20.5%;
p = 0.212, not significant), pontine H3.1K27M and ACVR1
(28/33, 84.8%; p < 0.0001), and PXA-like GBM with BRAF
V600E (17/28, 60.7%; p < 0.0001), we also identified previously
unrecognized co-segregating mutations including H3.3G34R/V
and ARID1B (2/20, 10%; p = 0.0720), H3.3K27M DIPG and
ATM and ASXL1 (5/93, 10.7%; p = 0.0473), and H3.1K27M
and BCOR (6/37, 16.2%; p = 0.0022, all Fisher’s exact test) (Fig-
ure S6D). We also identified recurrent events in genes such as
PTPN23 (protein tyrosine phosphatase, non-receptor type 23,
n = 5), SOX10 (SRY-box 10, n = 5), SRCAP (Snf2-related
CREBBP activator protein, n = 5),DEPDC5 (DEP domain-contain
5, member of GATOR complex, n = 4), SGK223 (PEAK1-related
kinase activating pseudokinase, n = 4), and others (Figure 6B).
Integrated Pathway Analysis
Many of the rare variants we identified (Figure S6E) were found
in genes associated with intracellular signaling pathways and
processes more commonly targeted by high-frequency events,
often in a mutually exclusive manner. In total, 297/326 (91.1%)
of cases were found to harbor genetic alterations in one or
more of nine key biological processes (Figure 7A). These
included well-recognized pathways such as DNA repair (198/
326, 60.7%), largely driven by TP53 mutations (n = 160), but
also by common mutually exclusive (p < 0.0001, Fisher’s exact
test) activating truncating alterations in PPM1D (n = 18), as well
as heterozygous mutations in a diverse set of genes including
those involved in homologous recombination (ATM, BRCA2,
BLM, ATR, PALB2, RAD50, and RAD51C) and numerous Fan-
comi anemia genes (BRIP1, FANCM, FANCA, and FANCG),
among others (Figure S7A). Although TP53 is almost always
found in concert with H3.3G34R/V in the cerebral hemispheres,
these additional DNA repair pathway mutations were enriched inG profiled across one or more of seven different platforms (dark red, amplifi-
ns clustered by gene-level data across the whole genome. Age at diagnosis is
bars according to the included key.
ss all 834 cases, in order of frequency, and colored independently by both
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H3.3K27M DIPG (36/68, 52.9%). Also co-segregating with
H3.3G34R/V and TP53 is ATRX, although mutations/deletions
of the latter gene are also frequently found in conjunction with
H3.3K27M (28/54, 51.8%). ATRX accounts for a large proportion
of the cases harboring mutations in genes coding for chromatin
modifiers (54/118, 45.8%); however, there is a diverse set of
readers, writers, and erasers also targeted at lower frequency,
especially in DIPG, including the previously mentioned BCOR
(n = 14) and ASXL1 (n = 6) in addition to SETD2 (n = 8),
KDM6B (n = 6), SETD1B (n = 5), and ARID1B (n = 5) among
many others (Figure S7B).
While CDKN2A/CDKN2B deletions were almost entirely ab-
sent from DIPG (1/154, 0.65%), dysregulation of the G1/S
cell-cycle checkpoint was common throughout anatomical loca-
tions and subgroups (82/326, 25.2%), with amplifications of
CCND2 and deletions of CDKN2C predominating in the pons
(n = 5/7 and 5/5 DIPG, respectively), in contrast to recurrent
homozygous RB1 deletions and CDK6 amplifications (n = 6/7
and 4/6 hemispheric) (Figure S4A) (Figure S7C).
Subgroup-specific dysregulation was also observed when
considering discrete components of the RTK-PI3K-MAPK
pathway. In total, 201/326 (61.7%) cases harbored alterations
in any given node; however, for H3.3G34R/V this was predomi-
nantly at the RTK level (11/20, n = 9 PDGFRA) (Figure S7D),
whereas H3.1K27M cases were enriched for PI3K/mTOR alter-
ations (17/37, n = 9 PIK3CA, n = 5 PIK3R1) (Figure S7E), and
H3 WT cases harbored the highest frequency of MAPK alter-
ations (mainly BRAF V600E in PXA-like, n = 5/10 plus one NF1)
(Figure S7F). NRTK1-NRTK3 fusions were enriched in the infant
group (4/6 fusions under 1 year old, median age 3.25 versus 8.5
years, p = 0.00033, t test) (Figure S7D). We further identified
mutations in genes regulating mTOR signaling, including TSC2
(n = 3), RPTOR, andMTOR itself (both n = 2), as well as a diverse
series of SNVs and fusion candidates in MAPKs across all sub-
groups and locations (MAP2K7,MAP3K15,MAP3K4 and others)
(Figure S7F).
BMP signaling was significantly enriched in H3.1K27M DIPG
due to the strong correlation with ACVR1 mutations; however,
alterations in other pathway members such as amplification of
ID2 (n = 10) or ID3 (n = 3) and mutations in BMP3 (n = 5),
BMP2K (n = 3), and others across locations and subgroups, ex-
tends the proportion of tumors for which this pathway may be
relevant (62/326, 18.7%) (Figure S7G). There was also a subset
of cases harboring alterations in members of the WNT signaling
pathway (16/326, 4.9%), includingAMER1, APC (both n = 3), and
WNT8A, WNT9A, PLAGL2, and TCF7L2 (all n = 2) (Figure S7H).
Uniquely, the accumulated data uncovered a series of addi-
tional processes involved in maintenance of DNA replication,
genome integrity, or transcriptional fidelity, targeted by infre-
quent but mutually exclusive alterations in pHGG and DIPG.Figure 4. Subgroup-specific Copy-Number Changes in pHGG/DIPG
(A) Heatmap representation of segmented DNA copy number for 705 pHGG/DIPG
gain; dark blue, deletion; blue, loss). Samples are arranged in columns clustered b
annotations are provided as bars according to the included key.
(B) GISTIC analysis of focal amplifications and deletions for histonemutation subg
red) and deletions (dark blue), with significantly enriched events labeled by likely d
(C) Barplot of frequency of whole chromosomal arm gains (red) and losses (blue) f
test) are labeled, with subgroup-specific arm changes highlighted by the appropThese included mutations in splicing factors (SF3A1, SF3A2,
SF3A3, SF3B1, SF3B2, and SF3B3, total n = 10), sister chro-
matid segregation (STAG2, STAG3, and ESPL1, total n = 9),
pre-miRNA processing (DICER and DROSHA, total n = 4), DNA
polymerases (POLK, POLQ, and POLR1B, total n = 4), as well
as genes involved in centromere (CENPB, n = 3) and telomere
maintenance (PML, n = 2; TERT, n = 7) (Figure S7I). TERT pro-
moter mutations were found in 5/326 (1.5%) cases; however,
alternative lengthening of telomeres (ALT) status was only avail-
able for 26 cases, although the 5 ALT-positive samples (19.2%)
were mutually exclusive with TERT alterations.
We incorporated the integrated dataset into a pathway enrich-
ment analysis (significant gene sets, false discovery rate [FDR] <
0.05, visualized as interaction networks by Cytoscape Enrich-
ment Map) in order to gain additional insight into dysregulated
biological processes. In addition to the subgroup-specific differ-
ential targeting of distinct nodes within common signaling path-
ways already described (e.g., RTK, PI3K/mTOR, and MAPK),
additional dysregulated processes across the diversity of the
disease were identified (Figure 7B). This revealed the perhaps
not unexpected dysregulation of numerous developmental and
CNS-associated gene sets (various immature organ systems,
neuronal communication), but also previously unrecognized
areas such as nuclear transport, cell migration, and the immune
response (Table S7), which may provide further insight into dis-
ease biology aswell as represent potential therapeutic strategies
targeting key regulators of tumor phenotype. Indeed, neuronal
communication with pGBM and DIPG cells is a recently demon-
strated microenvironmental driver of pediatric glioma growth
(Qin et al., 2017; Venkatesh et al., 2015).
Histone H3/IDH1 WT Subgroups
Finally, we wanted to explore those cases absent of any histone
H3 or IDH1 mutations in more depth. Using a t statistic-based
stochastic neighbor embedding projection of the 450k methyl-
ation data, we identified three distinct clusters of tumors sepa-
rate from the G34, K27, and IDH1 groups (Figure 8A). Consensus
clustering of the H3/IDH1 WT cases alone confirmed the pres-
ence of three robust subgroups (Figure 8B), which were also
recapitulated by unsupervised hierarchical clustering of the
10,000 probe classifier subset (Figure 8C). These groups
included a largely hemispheric set of tumors containing, but
not restricted to, the PXA- and LGG-like subgroups (WT-A).
These tumors were driven byBRAF V600E,NF1mutations, or fu-
sions in RTKs includingMET, FGFR2, and NTRK2,3 (Figure 8D).
Although including many younger patients, the ages varied
widely (Figure 8E). Regardless, this group had the best overall
survival (median = 63 months, p < 0.0001 versus rest, log rank
test) (Figure 8F), with the non-PXA/LGG-like tumors within this
group themselves having an extended median survival time ofseparated for known histone mutation subgroup (dark red, amplification; red,
y gene-level data across the whole genome. Clinicopathological andmolecular
roups. Log10 values are plotted across the genome for both amplifications (dark
river genes. Subgroup-specific genes are highlighted by the appropriate color.
or each subgroup. Significantly enriched alterations (p < 0.0001, Fisher’s exact
riate color. See also Figure S4 and Table S4.
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Figure 5. Alterations Targeting FBXW7 in H3.3G34R/V pHGG and TOP3A in H3.3K27M DIPG
(A) Segmented exon-level DNA copy-number heatmaps for 4q loss in H3.3G34R/V tumors (dark red, amplification; red, gain; dark blue, deletion; blue, loss; n =
28). An ideogram of chromosome 4 is provided indicating enlarged genome browser view and genes within common regions targeted across samples (gray).
Clinicopathological and molecular annotations are provided as bars according to the included key.
(B) Cartoon representation of amino acid position for four somaticmutations found in FBXW7, colored by annotated functional domains and numbers provided for
recurrent variants.
(C) Boxplots representing gene expression differences between FBXW7 lost/mutated cases (blue) and those with normal copy/WT (gray) in three independent
gene expression platform datasets. The thick line within the box is the median, the lower and upper limits of the boxes represent the first and third quartiles, and
the whiskers 1.53 the interquartile range.
(D) Segmented exon-level DNA copy-number heatmaps for 17p11.2 amplification in predominantly H3.3K27MDIPG (dark red, amplification; red, gain; dark blue,
deletion; blue, loss; n = 17). Chromosome 17 ideogram is provided indicating enlarged genome browser view and genes within common regions targeted across
samples (gray). Clinicopathological and molecular annotations are provided as bars according to the included key.
(legend continued on next page)
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38 months (p = 0.00928 versus other H3/IDH1 WTs, log rank
test). Taking an integrated gene expression profiling dataset
(Figures S8A–S8E), these tumors were found to have upregula-
tion of gene signatures associated with cytokine signaling and
cell junction organization (Figures S8F andS8G). A second group
of tumors (WT-B) were found in all anatomical compartments,
and were distinguished by chromosome 2 gains (Figure 8C)
and, most notably, by high-level amplifications in EGFR, CDK6,
and MYCN (p = 0.00033, p = 0.0299, p = 0.00037, respectively,
Fisher’s exact test), with an imperfect overlay to the classifier
‘‘GBM_pedRTK’’ and ‘‘GBM_MYCN’’ groups (Figure 8D). This
group had strong upregulation of MYC target genes, and had
the poorest overall survival (median = 14 months) (Figure 8F).
The remaining cases encompassed a methylation classifier
group described as ‘‘HGG_MID,’’ although in fact were split
80:20 hemispheric:midline (WT-C) (Figure 8C). This group was
enriched for chromosome 1p and 20q loss, 17q gain (p =
0.00595, p = 0.0286, p = 0.0478, respectively, Fisher’s exact
test) (Figure 8C), harbored PDGFRA and MET amplifications
(p = 0.0159, Fisher’s exact test) (Figure 8D), and was strongly
associated with the adult GBM-defined ‘‘Proneural’’ gene signa-
ture. These patients had a median survival of 18 months.
Although there remain tumors without detectable genetic al-
terations, we are nonetheless able to assign clinically meaningful
subgroups with plausible driver alterations to the vast majority of
pediatric HGG/DIPG.
DISCUSSION
Integrated molecular profiling has revolutionized the study of
diffusely infiltrating high-grade glial tumors in children, providing
evidence for unique mechanisms of molecular pathogenesis re-
flecting their distinct developmental origins (Baker et al., 2015;
Jones and Baker, 2014). Although they are relatively rare, the
present study accumulates 1,067 unique cases, a number
similar to the aggregated analysis of the The Cancer Genome
Atlas adult LGG/GBM cohorts (n = 1122, with grade III included
in the ‘‘lower-grade’’ series) (Ceccarelli et al., 2016). Although
there are clearly the usual caveats with such retrospective ana-
lyses of inconsistently annotated and treated cases, the cohort
appears to represent a clinically useful approximation of the di-
versity of the pHGG/DIPG population.
In adults, the key distinction is between IDH1mutant (G-CIMP/
ATRX/TP53 or 1p19q co-deleted/TERT promoter mutated) and
WT (classical, mesenchymal, PA-like) (Ceccarelli et al., 2016),
whereas in the childhood setting IDH1mutations were restricted
to a small proportion (6.25%) of tumors mostly in adolescents
(representing the tail end of an overwhelmingly adult disease),
and harbored only rare examples of the common alterations
seen inWT adult GBM (e.g., 4.9% EGFRmutation/amplification).
Instead, most prominent among the differences between pediat-
ric and adult studies is the frequency of hotspot mutations in
genes encoding histone H3 variants: 2/820 (0.2%) in adults(E) Sequencing coverage (top) and log2 ratio plot (bottom) for chromosomes 7,
arrangements leading to specific copy-number amplification of TOP3A.
(F) Boxplots representing gene expression differences between TOP3A amplifi
expression platform datasets. The thick line within the box is the median, the low
whiskers 1.53 the interquartile range. See also Figure S5 and Table S5.(Ceccarelli et al., 2016) versus 449/893 (50.3%) in the present
pHGG/DIPG series.
The importance of recurrent H3 mutations in the childhood
setting has become increasingly clear since their unexpected
discovery in 2012 (Schwartzentruber et al., 2012; Wu et al.,
2012), with clear clinicopathological differences associated
with distinct variants (Jones and Baker, 2014; Jones et al.,
2016; Sturm et al., 2014), and fundamental insights into mecha-
nisms of epigenetically linked tumorigenesis (Bender et al., 2013;
Bjerke et al., 2013; Chan et al., 2013; Funato et al., 2014). Despite
this, precisely how we can target these mutations clinically
remains elusive (Grasso et al., 2015; Hennika et al., 2017). Data
from such a large series of tumors demonstrates the robustness
of the histone-defined subgroups in terms of anatomical
location, age of incidence, clinical outcome, methylation and
gene expression profiles, copy-number changes, co-segre-
gating somatic mutations, and pathway dysregulation. As most
of the non-histone molecular alterations previously reported in
pHGG/DIPG have been relatively infrequent, it is only through
this accumulated dataset that we have been able to uncover
subgroup-specific genes/processes that may play a role as
diagnostic, prognostic, or predictive markers or drug targets in
these diseases.
H3.3G34R/V-mutant tumors are restricted to the cerebral
hemispheres and co-segregate with ATRX and TP53 mutations;
they are also the only pediatric subgroup to harbor frequent
MGMT promoter methylation (Korshunov et al., 2015). Copy-
number profiling of 63 cases highlighted a significant enrich-
ment of chromosomal arm losses at 3q, 4q, 5q, and 18q, further
refined by smallest region of overlap and GISTIC analyses. At
4q31.3, this identified FBXW7 as a candidate gene target of
the loss. FBXW7 encodes a member of the F box protein family
and is frequently deleted/mutated in cancer, supporting its tu-
mor-suppressive function (Davis et al., 2014); notably in relation
to H3.3G34R/V it has been reported to play a role in MYC/
MYCN stabilization through its action as a component of the
SCF-like ubiquitin ligase complex that targets MYC/MYCN for
proteasomal degradation (Welcker et al., 2004; Yada et al.,
2004). With MYCN upregulated in H3.3G34R/V tumors through
differential H3K36me3 binding (Bjerke et al., 2013), this obser-
vation adds to the mechanisms by which Myc proteins exert
their influence in this subgroup, and provide further rationale
for the observed effects of disrupting these interactions, such
as with Aurora kinase A inhibitors which target the direct inter-
action between the catalytic domain of Aurora A and a site
flanking Myc Box I that also binds SCF/FbxW7 (Richards
et al., 2016).
H3.3K27M tumors are found in two-thirds of DIPG and non-
brainstem midline pHGG alike, where they are associated with
a shorter overall survival in both locations, as well as in the small
number of cases reported in the cortex. Although presumably re-
flecting a common or overlapping origin, the pattern of co-segre-
gating mutations differ, e.g., PDGFRA alterations predominating17, and 20 for two cases, showing complex intra- or inter-chromosomal re-
ed cases (red) and those with normal copy (gray) in three independent gene
er and upper limits of the boxes represent the first and third quartiles, and the
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Figure 6. Somatic Mutations in pHGG/DIPG
(A) Oncoprint representation of an integrated annotation of somatic mutations and DNA copy-number changes for the 30 most frequently altered genes in 326
pHGG/DIPG (n R 6, frequency barplot on the right). Selected common fusion events are also shown where available. Samples are arranged in columns with
genes labeled along rows. Age at diagnosis is provided below. Underneath, barplots are provided on a log10 scale for numbers of copy-number aberrations and
somatic mutations per case. Clinicopathological and molecular annotations are provided as bars according to the included key.
(B) Barplot of all recurrent somatic mutations across all 326 cases, in order of frequency, and colored independently by both anatomical location and histone
mutation. See also Figure S6 and Table S6.
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Figure 7. Integrated Pathway Analysis of pHGG/DIPG
(A) Oncoprint-style representation of an integrated annotation of somatic mutations and DNA copy-number changes in one or more of nine commonly targeted
pathways in 326 pHGG/DIPG (nR 6, frequency barplot on the right). Samples are arranged in columnswith pathways labeled along rows. Clinicopathological and
molecular annotations are provided as bars according to the included key.
(B) Pathway enrichment analysis of pHGG/DIPG subgroups. Distinct pathways and biological processes between the subgroups are colored appropriately (FDR
q< 0.01). Nodes represent enriched gene sets, which are grouped and annotated by their similarity according to related gene sets. Node size is proportional to the
total number of genes within each gene set. The illustrated network map was simplified by manual curation to remove general and uninformative sub-networks.
See also Figure S7 and Table S7.in the pons, and FGFR1 variants being largely restricted to the
thalamus (Fontebasso et al., 2014). Our analysis of more than
300 cases further identifies differential amplification of CCND2
(DIPG) and CDK4 (non-brainstem midline), and, most strikingly,
an amplification at 17p11.2 involving TOP3A in H3.3K27M
DIPG. This complex rearrangement often involves loss of the
more distal part of 17p involving TP53, along with intra- or
inter-chromosomal translocations to deliver an increase in
TOP3A copy number and gene expression. TOP3A encodesDNA topoisomerase III alpha, which forms a complex with
BLM (Wu et al., 2000), has an important role in homologous
recombination (Yang et al., 2010), and has been implicated in
maintenance of the ALT phenotype (Temime-Smaali et al.,
2009). Notably, TOP3A amplification/mutation was found to be
mutually exclusive with ATRX mutation in H3.3K27M DIPG,
with depletion by small interfering RNA reducing ALT cell survival
(Temime-Smaali et al., 2008), and therefore represents a poten-
tial therapeutic target in this subgroup.Cancer Cell 32, 520–537, October 9, 2017 533
Figure 8. Integrated Analysis of H3/IDH1 WT pHGG/DIPG
(A) t Statistic-based stochastic neighbor embedding (t-SNE) projection of the combined 450k methylation dataset (n = 441). The first three projections are plotted
in the x, y, and z axes, with samples represented by dots colored by histone H3G34 (blue), H3K27 (green), IDH1 (red), PXA-like (dark gold), LGG-like (tan), and
‘‘others’’ (gray).
(B) Kmeans consensus clustering on the H3/IDH1WT cases highlights three stable clusters (left, black/brown [WT-A], gray/pink [WT-B], and dark cyan [WT-C]) as
the most robust subdivision of the data (right, area under the curve analysis for different cluster numbers).
(C) Unsupervised hierarchical clustering and attendant heatmap of the H3/IDH1 WT cases (n = 219). Samples are arranged in columns clustered by the most
variable 1,521 classifier probes. Age at diagnosis is provided below. Clinicopathological and molecular annotations are provided as bars according to the
included key.
(D) Oncoprint representation of an integrated annotation of somatic mutations and DNA copy-number changes for the H3/IDH1 WT cases (n = 50). Samples are
arranged in columns with genes labeled along rows. Age at diagnosis is provided below. Clinicopathological and molecular annotations are provided as bars
according to the included key.
(E) Boxplot showing age at diagnosis of H3/IDH1WT subgroups, separated by anatomical location (n = 190). The thick line within the box is the median, the lower
and upper limits of the boxes represent the first and third quartiles, and the whiskers 1.53 the interquartile range.
(F) Kaplan-Meier plot of overall survival of H3/IDH1 WT subgroups separated by anatomical location, p value calculated by the log rank test (n = 150). See also
Figure S8 and Table S8.
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H3.1K27M tumors by contrast are restricted to the pons, pa-
tients are younger and with a slightly longer survival (Castel
et al., 2015), and are largely defined at the copy-number level
by whole chromosomal arm gains and losses (Taylor et al.,
2014a). They have the well-recognized association with ACVR1
mutation (Taylor et al., 2014b); however, we also identify an
enrichment of downstream PI3K pathway mutations (PIK3CA
and PIK3R1) in comparison with the largely upstream RTK alter-
ations present in H3.3K27MDIPGs, important in designing strat-
ified trials and combinatorial therapies. Further association with
mutations of the BCL6 repressor gene BCOR, commonly altered
in medulloblastomas, neuroepithelial tumors, and sarcomas,
highlights a further avenue for interventional study through its
regulation of the SHH pathway (Tiberi et al., 2014).
In H3/IDH1 WT cases, methylation profiling refines the hetero-
geneous collection of tumors, particularly identifying two pre-
dominantly hemispheric intermediate risk subgroups that clas-
sify alongside other entities (PXA- and LGG-like) in a larger
series of better outcome tumors (WT-A). These had already
been strongly linked with dysregulation of the MAPK pathway
(BRAF V600E) (Korshunov et al., 2015) along with CDKN2A/
CDKN2B deletion (Nicolaides et al., 2011). However, with molec-
ular markers such as losses at 1q and 17p appearing to confer a
worse outcome theremay bemore than one subgroupwithin this
entity, and a co-clustering group of H3/IDH1 WT tumors ap-
peared distinctly driven by somatic NF1 mutation. The LGG-
like tumors generally occur in very young patients, where the
appearance of few genetic alterations and a significantly better
prognosis is shared by the majority of infant HGG. Gene fusion
events, including those targeting NTRKs1-NTRK3, are common
in this age range. Notably this enhanced survival is restricted to
patients diagnosed under 12 months of age, and is not recapit-
ulated in the 1–3 year age group, although this is the common
clinical definition of ‘‘infants’’ in many centers.
Excluding these morphologically high-grade but biologically
and clinically low-grade tumors, the remaining H3/IDH1 WT
cases can be further split into two poor-outcome groups driven
by EGFR/MYCN/CDK6 (WT-B) or PDGFRA/MET (WT-C) or am-
plifications. These groups overlap with other methylation-based
classification groups (PDGFRA versus EGFR versusMYCN (Kor-
shunov et al., 2017); ‘‘GBM_pedRTK’’ versus ‘‘GBM_MYCN’’
versus ‘‘HGG_MID’’ (molecularneuropathology.org/mnp), how-
ever, are uniquely defined here spanning anatomical locations
and integrated with sequencing data. Further exploration of
these heterogeneous subgroups in order to refine integrated
molecular diagnostics to prioritize patient subpopulations for
stratified treatment remains a priority.
The remarkable biological diversity spanning pediatric malig-
nant glioma is finally demonstrated by the <5% tumors with a hy-
permutator phenotype, some of the greatest mutational burdens
in all human cancer, and candidates for immune checkpoint
inhibitors (Bouffet et al., 2016). Previously unrecognized pro-
cesses altered in small subsets of tumors identified through
this meta-analysis, such as the splicing machinery, miRNA regu-
lation, and the WNT pathway offer further areas for exploration.
The thorough cataloging of dysregulated molecular pathways
across the whole spectrum of pediatric diffusely infiltrating gli-
omas in the present study provides the basis for novel therapeu-
tic development.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d CONTACT FOR REAGENT AND RESOURCE SHARING
d EXPERIMENTAL MODEL AND SUBJECT DETAILSB Patient Samples
d METHOD DETAILS
B Nucleic Acid Extraction
B Sanger Sequencing of H3F3A / HIST1H3B
B Methylation Profiling
B Exome and RNA Sequencing
d QUANTIFICATION AND STATISTICAL ANALYSIS
B Published Data Sources
B DNA Copy Number
B DNA Methylation
B mRNA Expression
B Sequence Analysis
B Candidate Fusion Gene Nomination
B Inferred Tumor Purity
B Integrated Analysis of Driver Events
B Pathway Analysis
B Statistical Analysis
d DATA AND SOFTWARE AVAILABILITY
d ADDITIONAL RESOURCES
SUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures and eight tables and can be
found with this article online at http://dx.doi.org/10.1016/j.ccell.2017.08.017.
AUTHOR CONTRIBUTIONS
A.M., M.F., A.O.v.B., M.B., and C.J. conceived the study. A.M. and C.J.
analyzed data and wrote the manuscript. A.B., D.C., E.I.D., J.F.S., K.T., L.B.,
M.V., M.N., S.T., and V.M. performed molecular analysis of unpublished sam-
ples. M.C., S.P., L.R.B., S.A.-S., A.N.K., D.M.K., K.M., K.-K.N., M.S., and C.K.
carried out histopathological assessment of cases. M.M., J.G., C.H., N.J.,
S.J.B., S.M.P., and D.T.W.J. provided data. L.M., S.Z., S.V., H.C.M., A.J.M.,
C.C., N.E.-W., J.P., J.S., R.M.R., A.S.M., L.S., S.T., D.H.-B.B., A.M.C.,
C.d.T., O.C., J.M., and M.M. provided samples and clinical annotation. M.B.,
P.R., A.J.W., H.J.H., S.G., and A.R. constructed analytical and visualization
tools and databases. All authors approved the manuscript.
ACKNOWLEDGMENTS
This work was supported by Cancer Research UK (grants C13468/A13982 and
C13468/A23536), CRIS Cancer Foundation, Abbie’s Army and the DIPG
Collaborative, the Cure Starts NowFoundation, Christopher’s Smile, McKenna
Claire Foundation, Lyla Nsouli Foundation, National Institutes of Health (grants
R01NS085336 and R01NS091620), The Dragon Master Foundation, The Kort-
ney Rose Foundation, TheMusella Foundation For Brain Tumor Research & In-
formation, Gray Matters Foundation, Pediatric Brain Tumor Foundation, and
the INSTINCT network funded by The Brain Tumour Charity, Great Ormond
Street Children’s Charity, and Children with Cancer UK. The authors acknowl-
edge NHS funding to the NIHR Biomedical Research Centre at The Royal
Marsden and the ICR. LTB was recipient of Sa˜o Paulo Research Foundation
fellowships (2011/08523-7 and 2012/08287-4). This study makes use of data
generated by the St. Jude Children’s Research Hospital – Washington Univer-
sity Pediatric Cancer Genome Project, the Hospital for Sick Children, the
McGill University-DKFZ Pediatric Brain Tumor Consortium, the International
Cancer Genomics Consortium PedBrain Project and the Cancer ResearchCancer Cell 32, 520–537, October 9, 2017 535
UK Genomics Initiative (C13468/A14078) and supports the Children’s Brain
Tumor Tissue Consortium and The Pacific Pediatric Neuro-Oncology Con-
sortium (PNOC) CAVATICA: Project OPEN DIPG initiative.
Received: May 5, 2017
Revised: July 14, 2017
Accepted: August 29, 2017
Published: September 28, 2017
REFERENCES
Baker, S.J., Ellison, D.W., andGutmann, D.H. (2015). Pediatric gliomas as neu-
rodevelopmental disorders. Glia 64, 879–895.
Barrow, J., Adamowicz-Brice, M., Cartmill, M., MacArthur, D., Lowe, J.,
Robson, K., Brundler, M.A., Walker, D.A., Coyle, B., and Grundy, R. (2011).
Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric
high-grade glioma and diffuse intrinsic pontine gliomas. Neuro Oncol. 13,
212–222.
Bax, D.A., Mackay, A., Little, S.E., Carvalho, D., Viana-Pereira, M., Tamber, N.,
Grigoriadis, A.E., Ashworth, A., Reis, R.M., Ellison, D.W., et al. (2010). A distinct
spectrum of copy number aberrations in pediatric high-grade gliomas. Clin.
Cancer Res. 16, 3368–3377.
Bender, S., Tang, Y., Lindroth, A.M., Hovestadt, V., Jones, D.T., Kool, M.,
Zapatka, M., Northcott, P.A., Sturm, D., Wang, W., et al. (2013). Reduced
H3K27me3 and DNA hypomethylation are major drivers of gene expression
in K27M mutant pediatric high-grade gliomas. Cancer Cell 24, 660–672.
Bjerke, L., Mackay, A., Nandhabalan, M., Burford, A., Jury, A., Popov, S., Bax,
D.A., Carvalho, D., Taylor, K.R., Vinci, M., et al. (2013). Histone H3.3. mutations
drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov. 3,
512–519.
Bouffet, E., Larouche, V., Campbell, B.B., Merico, D., de Borja, R., Aronson,
M., Durno, C., Krueger, J., Cabric, V., Ramaswamy, V., et al. (2016). Immune
checkpoint inhibition for hypermutant glioblastoma multiforme resulting from
germline biallelic mismatch repair deficiency. J. Clin. Oncol. 34, 2206.
Buczkowicz, P., Hoeman, C., Rakopoulos, P., Pajovic, S., Letourneau, L.,
Dzamba, M., Morrison, A., Lewis, P., Bouffet, E., Bartels, U., et al. (2014).
Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular
subgroups and recurrent activating ACVR1 mutations. Nat. Genet. 46,
451–456.
Cai, H., Kumar, N., and Baudis, M. (2012). arrayMap: a reference resource for
genomic copy number imbalances in human malignancies. PLoS One 7,
e36944.
Cai, H., Kumar, N., Ai, N., Gupta, S., Rath, P., and Baudis, M. (2014).
Progenetix: 12 years of oncogenomic data curation. Nucleic Acids Res. 42,
D1055–D1062.
Carvalho, D., Mackay, A., Bjerke, L., Grundy, R.G., Lopes, C., Reis, R.M., and
Jones, C. (2014). The prognostic role of intragenic copy number breakpoints
and identification of novel fusion genes in paediatric high grade glioma. Acta
Neuropathol. Commun. 2, 23.
Castel, D., Philippe, C., Calmon, R., Le Dret, L., Truffaux, N., Boddaert, N.,
Pages, M., Taylor, K.R., Saulnier, P., Lacroix, L., et al. (2015). Histone H3F3A
and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic
pontine gliomas with different prognosis and phenotypes. Acta Neuropathol.
130, 815–827.
Ceccarelli, M., Barthel, F.P., Malta, T.M., Sabedot, T.S., Salama, S.R., Murray,
B.A., Morozova, O., Newton, Y., Radenbaugh, A., Pagnotta, S.M., et al. (2016).
Molecular profiling reveals biologically discrete subsets and pathways of pro-
gression in diffuse glioma. Cell 164, 550–563.
Chan, K.M., Fang, D., Gan, H., Hashizume, R., Yu, C., Schroeder, M., Gupta,
N., Mueller, S., James, C.D., Jenkins, R., et al. (2013). The histone H3.3K27M
mutation in pediatric glioma reprograms H3K27 methylation and gene expres-
sion. Genes Dev. 27, 985–990.
Davis, R.J., Welcker, M., and Clurman, B.E. (2014). Tumor suppression by
the Fbw7 ubiquitin ligase: mechanisms and opportunities. Cancer Cell 26,
455–464.536 Cancer Cell 32, 520–537, October 9, 2017Fontebasso, A.M., Schwartzentruber, J., Khuong-Quang, D.A., Liu, X.Y.,
Sturm, D., Korshunov, A., Jones, D.T., Witt, H., Kool, M., Albrecht, S., et al.
(2013). Mutations in SETD2 and genes affecting histone H3K36 methylation
target hemispheric high-grade gliomas. Acta Neuropathol. 125, 659–669.
Fontebasso, A.M., Papillon-Cavanagh, S., Schwartzentruber, J., Nikbakht, H.,
Gerges, N., Fiset, P.O., Bechet, D., Faury, D., De Jay, N., Ramkissoon, L.A.,
et al. (2014). Recurrent somatic mutations in ACVR1 in pediatric midline
high-grade astrocytoma. Nat. Genet. 46, 462–466.
Funato, K., Major, T., Lewis, P.W., Allis, C.D., and Tabar, V. (2014). Use of hu-
man embryonic stem cells to model pediatric gliomas with H3.3K27M histone
mutation. Science 346, 1529–1533.
Grasso, C.S., Tang, Y., Truffaux, N., Berlow, N.E., Liu, L., Debily, M.A., Quist,
M.J., Davis, L.E., Huang, E.C., Woo, P.J., et al. (2015). Functionally defined
therapeutic targets in diffuse intrinsic pontine glioma. Nat. Med. 21, 555–559.
Hennika, T., Hu, G., Olaciregui, N.G., Barton, K.L., Ehteda, A., Chitranjan, A.,
Chang, C., Gifford, A.J., Tsoli, M., Ziegler, D.S., et al. (2017). Pre-clinical study
of panobinostat in xenograft and genetically engineered murine diffuse
intrinsic pontine glioma models. PLoS One 12, e0169485.
International Cancer Genome Consortium PedBrain Tumor Project (2016).
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.
Nat. Med. 22, 1314–1320.
Jones, C., and Baker, S.J. (2014). Unique genetic and epigenetic mechanisms
driving paediatric diffuse high-grade glioma. Nat. Rev. Cancer 14, 651–661.
Jones, C., Perryman, L., and Hargrave, D. (2012). Paediatric and adult malig-
nant glioma: close relatives or distant cousins? Nat. Rev. Clin. Oncol. 9,
400–413.
Jones, C., Karajannis, M.A., Jones, D.T., Kieran, M.W., Monje, M., Baker, S.J.,
Becher, O.J., Cho, Y.J., Gupta, N., Hawkins, C., et al. (2016). Pediatric high-
grade glioma: biologically and clinically in need of new thinking. Neuro
Oncol. 19, 153.
Khuong-Quang, D.A., Buczkowicz, P., Rakopoulos, P., Liu, X.Y., Fontebasso,
A.M., Bouffet, E., Bartels, U., Albrecht, S., Schwartzentruber, J., Letourneau,
L., et al. (2012). K27M mutation in histone H3.3 defines clinically and biologi-
cally distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta
Neuropathol. 124, 439–447.
Korshunov, A., Ryzhova, M., Hovestadt, V., Bender, S., Sturm, D., Capper, D.,
Meyer, J., Schrimpf, D., Kool, M., Northcott, P.A., et al. (2015). Integrated
analysis of pediatric glioblastoma reveals a subset of biologically favorable tu-
mors with associated molecular prognostic markers. Acta Neuropathol. 129,
669–678.
Korshunov, A., Schrimpf, D., Ryzhova, M., Sturm, D., Chavez, L., Hovestadt,
V., Sharma, T., Habel, A., Burford, A., Jones, C., et al. (2017). H3-/IDH-wild
type pediatric glioblastoma is comprised of molecularly and prognostically
distinct subtypes with associated oncogenic drivers. Acta Neuropathol.
http://dx.doi.org/10.1007/s00401-017-1710-1.
Kramm, C.M., Butenhoff, S., Rausche, U.,Warmuth-Metz, M., Kortmann, R.D.,
Pietsch, T., Gnekow, A., Jorch, N., Janssen, G., Berthold, F., et al. (2011).
Thalamic high-grade gliomas in children: a distinct clinical subset? Neuro
Oncol. 13, 680–689.
Louis, D.N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D.,
Cavenee, W.K., Ohgaki, H., Wiestler, O.D., Kleihues, P., and Ellison, D.W.
(2016). The 2016World Health Organization classification of tumors of the cen-
tral nervous system: a summary. Acta Neuropathol. 131, 803–820.
Nicolaides, T.P., Li, H., Solomon, D.A., Hariono, S., Hashizume, R., Barkovich,
K., Baker, S.J., Paugh, B.S., Jones, C., Forshew, T., et al. (2011). Targeted
therapy for BRAFV600E malignant astrocytoma. Clin. Cancer Res. 17,
7595–7604.
Northcott, P.A., Lee, C., Zichner, T., Stutz, A.M., Erkek, S., Kawauchi, D., Shih,
D.J., Hovestadt, V., Zapatka, M., Sturm, D., et al. (2014). Enhancer hijacking
activates GFI1 family oncogenes in medulloblastoma. Nature 511, 428–434.
Ostrom, Q.T., Gittleman, H., Fulop, J., Liu, M., Blanda, R., Kromer, C.,
Wolinsky, Y., Kruchko, C., and Barnholtz-Sloan, J.S. (2015). CBTRUS statisti-
cal report: primary brain and central nervous system tumors diagnosed in the
United States in 2008–2012. Neuro Oncol. 17 (Suppl 4 ), iv1–iv62.
Paugh, B.S., Qu, C., Jones, C., Liu, Z., Adamowicz-Brice, M., Zhang, J., Bax,
D.A., Coyle, B., Barrow, J., Hargrave, D., et al. (2010). Integratedmolecular ge-
netic profiling of pediatric high-grade gliomas reveals key differences with the
adult disease. J. Clin. Oncol. 28, 3061–3068.
Paugh, B.S., Broniscer, A., Qu, C., Miller, C.P., Zhang, J., Tatevossian, R.G.,
Olson, J.M., Geyer, J.R., Chi, S.N., da Silva, N.S., et al. (2011). Genome-
wide analyses identify recurrent amplifications of receptor tyrosine kinases
and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J. Clin.
Oncol. 29, 3999–4006.
Paugh, B.S., Zhu, X., Qu, C., Endersby, R., Diaz, A.K., Zhang, J., Bax, D.A.,
Carvalho, D., Reis, R.M., Onar-Thomas, A., et al. (2013). Novel oncogenic
PDGFRA mutations in pediatric high-grade gliomas. Cancer Res. 73,
6219–6229.
Puget, S., Philippe, C., Bax, D.A., Job, B., Varlet, P., Junier, M.P., Andreiuolo,
F., Carvalho, D., Reis, R., Guerrini-Rousseau, L., et al. (2012). Mesenchymal
transition and PDGFRA amplification/mutation are key distinct oncogenic
events in pediatric diffuse intrinsic pontine gliomas. PLoS One 7, e30313.
Qin, E.Y., Cooper, D.D., Abbott, K.L., Lennon, J., Nagaraja, S., Mackay, A.,
Jones, C., Vogel, H., Jackson, P.K., and Monje, M. (2017). Neural Precursor-
Derived Pleiotrophin Mediates Subventricular Zone Invasion by Glioma. Cell
170 (5), 845–859.
Richards, M.W., Burgess, S.G., Poon, E., Carstensen, A., Eilers, M., Chesler,
L., and Bayliss, R. (2016). Structural basis of N-Myc binding by Aurora-A
and its destabilization by kinase inhibitors. Proc. Natl. Acad. Sci. USA 113,
13726–13731.
Schiffman, J.D., Hodgson, J.G., VandenBerg, S.R., Flaherty, P., Polley, M.Y.,
Yu, M., Fisher, P.G., Rowitch, D.H., Ford, J.M., Berger, M.S., et al. (2010).
Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a
subset of pediatric malignant astrocytomas. Cancer Res. 70, 512–519.
Schwartzentruber, J., Korshunov, A., Liu, X.Y., Jones, D.T., Pfaff, E., Jacob, K.,
Sturm, D., Fontebasso, A.M., Quang, D.A., Tonjes, M., et al. (2012). Driver mu-
tations in histone H3.3 and chromatin remodelling genes in paediatric glioblas-
toma. Nature 482, 226–231.
Shlien, A., Campbell, B.B., de Borja, R., Alexandrov, L.B., Merico, D., Wedge,
D., Van Loo, P., Tarpey, P.S., Coupland, P., Behjati, S., et al. (2015). Combined
hereditary and somatic mutations of replication error repair genes result in
rapid onset of ultra-hypermutated cancers. Nat. Genet. 47, 257–262.
Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.A., Jones, D.T.,
Konermann, C., Pfaff, E., Tonjes, M., Sill, M., Bender, S., et al. (2012).
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological
subgroups of glioblastoma. Cancer Cell 22, 425–437.
Sturm, D., Bender, S., Jones, D.T., Lichter, P., Grill, J., Becher, O., Hawkins,
C., Majewski, J., Jones, C., Costello, J.F., et al. (2014). Paediatric and adult
glioblastoma: multiform (epi)genomic culprits emerge. Nat. Rev. Cancer
14, 92–107.
Taylor, K.R.,Mackay, A., Truffaux, N., Butterfield, Y.S., Morozova, O., Philippe,
C., Castel, D., Grasso, C.S., Vinci, M., Carvalho, D., et al. (2014a). Recurrentactivating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat. Genet.
46, 457–461.
Taylor, K.R., Vinci, M., Bullock, A.N., and Jones, C. (2014b). ACVR1 mutations
in DIPG: lessons learned from FOP. Cancer Res. 74, 4565–4570.
Temime-Smaali, N., Guittat, L., Wenner, T., Bayart, E., Douarre, C., Gomez, D.,
Giraud-Panis, M.J., Londono-Vallejo, A., Gilson, E., Amor-Gueret, M., et al.
(2008). Topoisomerase IIIalpha is required for normal proliferation and telo-
mere stability in alternative lengthening of telomeres. EMBO J. 27, 1513–1524.
Temime-Smaali, N., Guittat, L., Sidibe, A., Shin-ya, K., Trentesaux, C., and
Riou, J.F. (2009). The G-quadruplex ligand telomestatin impairs binding of
topoisomerase IIIalpha to G-quadruplex-forming oligonucleotides and uncaps
telomeres in ALT cells. PLoS One 4, e6919.
Tiberi, L., Bonnefont, J., van den Ameele, J., Le Bon, S.D., Herpoel, A., Bilheu,
A., Baron, B.W., and Vanderhaeghen, P. (2014). A BCL6/BCOR/SIRT1 com-
plex triggers neurogenesis and suppresses medulloblastoma by repressing
Sonic Hedgehog signaling. Cancer Cell 26, 797–812.
Venkatesh, H.S., Johung, T.B., Caretti, V., Noll, A., Tang, Y., Nagaraja, S.,
Gibson, E.M., Mount, C.W., Polepalli, J., Mitra, S.S., et al. (2015). Neuronal
activity promotes glioma growth through Neuroligin-3 secretion. Cell 161,
803–816.
Welcker, M., Orian, A., Jin, J., Grim, J.E., Harper, J.W., Eisenman, R.N., and
Clurman, B.E. (2004). The Fbw7 tumor suppressor regulates glycogen syn-
thase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc.
Natl. Acad. Sci. USA 101, 9085–9090.
Wu, L., Davies, S.L., North, P.S., Goulaouic, H., Riou, J.F., Turley, H., Gatter,
K.C., and Hickson, I.D. (2000). The Bloom’s syndrome gene product interacts
with topoisomerase III. J. Biol. Chem. 275, 9636–9644.
Wu, G., Broniscer, A., McEachron, T.A., Lu, C., Paugh, B.S., Becksfort, J., Qu,
C., Ding, L., Huether, R., Parker, M., et al. (2012). Somatic histone H3 alter-
ations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glio-
blastomas. Nat. Genet. 44, 251–253.
Wu, G., Diaz, A.K., Paugh, B.S., Rankin, S.L., Ju, B., Li, Y., Zhu, X., Qu, C.,
Chen, X., Zhang, J., et al. (2014). The genomic landscape of diffuse intrinsic
pontine glioma and pediatric non-brainstem high-grade glioma. Nat. Genet.
46, 444–450.
Yada, M., Hatakeyama, S., Kamura, T., Nishiyama, M., Tsunematsu, R., Imaki,
H., Ishida, N., Okumura, F., Nakayama, K., and Nakayama, K.I. (2004).
Phosphorylation-dependent degradation of c-Myc is mediated by the F-box
protein Fbw7. EMBO J. 23, 2116–2125.
Yang, J., Bachrati, C.Z., Ou, J., Hickson, I.D., and Brown, G.W. (2010). Human
topoisomerase IIIalpha is a single-stranded DNA decatenase that is stimulated
by BLM and RMI1. J. Biol. Chem. 285, 21426–21436.
Zarghooni, M., Bartels, U., Lee, E., Buczkowicz, P., Morrison, A., Huang, A.,
Bouffet, E., and Hawkins, C. (2010). Whole-genome profiling of pediatric
diffuse intrinsic pontine gliomas highlights platelet-derived growth factor re-
ceptor alpha and poly (ADP-ribose) polymerase as potential therapeutic tar-
gets. J. Clin. Oncol. 28, 1337–1344.Cancer Cell 32, 520–537, October 9, 2017 537
STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Critical Commercial Assays
DNeasy blood & tissue kit Qiagen 69504
QIAmp DNA FFPE tissue kit Qiagen 56404
RNeasy mini kit Qiagen 74104
QIAquick PCR purification kit Qiagen 28104
BigDye terminator v3.1 mix Thermo Fisher 4337455
SureSelect Human All Exon capture set V4
SureSelect Human All Exon capture set V5
Agilent 5190-4666
5190-6208
SureSelect RNA Capture, 0.5-2.9Mb Agilent 5190-4944
Deposited Data
Exome and RNA sequencing of new samples This paper EGA: EGAS00001002314
Illumina methylation BeadChip profiling of new
samples
This paper ArrayExpress:
E-MTAB-5528
Sequencing and methylation data This paper cavatica.org
Oligonucleotides
Primer: H3F3A_forward
TGGCTCGTACAAAGCAGACT
This paper N/A
Primer: H3F3A_reverse
ATATGGATACATACAAGAGAGACT
This paper N/A
Primer: HIST1H3B_forward
GGGCAGGAGCCTCTCTTAAT
This paper N/A
Primer: HIST1H3B _ reverse
ACCAAGTAGGCCTCACAAGC
This paper N/A
Software and Algorithms
Mutation Surveyor SoftGenetics softgenetics.com/mutationSurveyor.php
4Peaks Nucleobytes http://nucleobytes.com/4peaks/
limma BioConductor bioconductor.org/packages/release/bioc/
html/limma.html
marray BioConductor bioconductor.org/packages/release/bioc/
html/marray.html
aroma.affymetrix The Comprehensive
R Archive Network
cran.rstudio.com/web/packages/aroma.
affymetrix/index.html
aroma.cn The Comprehensive
R Archive Network
cran.r-project.org/web/packages/aroma.cn/
index.html
minfi BioConductor bioconductor.org/packages/release/bioc/
html/minfi.html
conumee BioConductor bioconductor.org/packages/release/bioc/
html/conumee.html
BEDtools University of Utah github.com/arq5x/bedtools2
DNAcopy BioConductor bioconductor.org/packages/release/bioc/
html/DNAcopy.html
gviz BioConductor bioconductor.org/packages/release/bioc/
html/Gviz.html
GISTIC Broad Institute oftware.broadinstitute.org/software/
cprg/?q=node/31
CopyNumber450kData BioConductor bioconductor.org/packages/release/data/
experiment/html/CopyNumber450kData.html
MNP DKFZ Heidelberg molecularneuropathology.org/mnp
(Continued on next page)
e1 Cancer Cell 32, 520–537.e1–e5, October 9, 2017
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
tSNE The Comprehensive
R Archive Network
cran.r-project.org/web/packages/Rtsne/
index.html
rgl The Comprehensive
R Archive Network
cran.r-project.org/web/packages/rgl/
index.html
affy BioConductor bioconductor.org/packages/release/
bioc/html/affy.html
Bowtie2 Johns Hopkins University bowtie-bio.sourceforge.net/bowtie2/
index.shtml
TopHat Johns Hopkins University ccb.jhu.edu/software/tophat/index.shtml
cufflinks University of Washington ole-trapnell-lab.github.io/cufflinks/
cufflinks/
DESeq2 BioConductor bioconductor.org/packages/release/
bioc/html/DESeq2.html
Gene Set Enrichment Analysis Broad Institute http://software.broadinstitute.org/gsea
bwa Sanger Institute http://bio-bwa.sourceforge.net/
Genome Analysis Toolkit Broad Institute oftware.broadinstitute.org/gatk/
Variant Effect predictor Ensembl tools ensembl.org/info/docs/variation/vep
ANNOVAR Children’s Hospital of Philadelphia annovar.openbioinformatics.org/en/latest/
ExAc Broad Institute exac.broadinstitute.org/
BCBio Harvard TH Chan bcb.io/
SIFT J Craig Venter Institute sift.jcvi.org
PolyPhen Harvard genetics.bwh.harvard.edu/pph2
ChimeraScan University of Michigan omictools.com/chimerascan-tool
Breakdancer Washington University of St Louis breakdancer.sourceforge.net
ASCAT Francis Crick Institute rick.ac.uk/peter-van-loo/software/ASCAT
Oncoprinter Memorial Sloan Kettering cbioportal.org/oncoprinter.jsp
ProteinPaint St Jude pecan.stjude.org/#/proteinpaint
Circos Michael Smith Genome
Sciences Center
circos.ca
MSigDB Broad Institute http://software.broadinstitute.org/gsea/
msigdb
CytoScape National Institute of
General Medical Sciences
cytoscape.org
R The Comprehensive
R Archive Network
r-project.org
Other
Processed DNA copy number profiles This paper and cited sources dipg.progenetix.org
arraymap.org
Integrated mutation, copy number,
expression and methylation data
This paper and cited sources pedcbioportal.orgCONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Chris
Jones (chris.jones@icr.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Patient Samples
All new patient material was collected after informed consent and subject to local research ethics committee approval. We collated
and profiled 157 unpublished cases of HGG in children and young adults up to the age of 30 years at diagnosis obtained from
the Royal Marsden, St Georges and Kings College Hospitals, (n=39, all London, UK), Chinese University of Hong Kong (n=24,Cancer Cell 32, 520–537.e1–e5, October 9, 2017 e2
Hong Kong, China), Qilu University Hospital (n=23, Jinan, China), Farhad Hatched Hospital (n=14, Sousse, Tunisia), Federal Univer-
sity of Sa˜o Paolo (n=14, Sa˜o Paulo, Brazil), Morozov Children’s and Dmitri Rogachev Hospitals (n=12, Moscow, Russia), Queensland
Children’s Tumor Bank (n=8, Brisbane, Australia), Hospital San Joan de De´u (n=8, Barcelona, Spain), City Hospital #31 (n=6, St Pe-
tersburg, Russia), Barretos Cancer Hospital (n=4, Barretos, Brazil), Centre Hospitalier Re´gional et Universitaire Hautepierre (n=3,
Strasbourg, France), and Our Lady Children’s Hospital Crumlin (n=2, Dublin, Ireland). A full description of the samples included
are provided in Table S1.
METHOD DETAILS
Nucleic Acid Extraction
DNAwas extracted from frozen tissue by homogenisation prior to following the DNeasy Blood & Tissue kit protocol (Qiagen, Crawley,
UK). DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) pathology blocks after manual macrodissection using
the QIAamp DNA FFPE tissue kit protocol (Qiagen). Matched normal DNA was extracted from blood samples using the DNeasy
Blood & Tissue kit (Qiagen, Crawley, UK). Concentrations were measured using a Qubit fluorometer (Life Technologies, Paisley,
UK). RNA was extracted by following the RNeasy Mini Kit protocol (Qiagen), and quantified on a 2100 Bioanalyzer (Agilent
Technologies).
Sanger Sequencing of H3F3A / HIST1H3B
PCR for H3F3A and HIST1H3B was carried out using primers obtained from Life Technologies (Paisley, UK). Products were purified
using the QIAquick PCR purification kit (Qiagen), subjected to bidirectional sequencing using BigDye Terminator mix 3.1 (Applied
Biosystems, Foster City, CA, USA), with capillary sequencing was done on an ABI 3100 genetic analyzer (Applied Biosystems, Foster
City, CA, USA). Sequenceswere analysed usingMutation Surveyor (SoftGenetics, PN, USA) andmanually with 4Peaks (Nucleobytes,
Aalsmeer, Netherlands).
Methylation Profiling
50-500 ng DNA was bisulphite-modified and analyzed for genome-wide methylation patterns using the Illumina
HumanMethylation450 BeadArray (450k) platform at either the DKFZ or the University College London Genomics Centre, according
the manufacturer’s instructions. All samples were checked for expected and unexpected genotype matches by pairwise correlation
of the 65 genotyping probes on the 450k array.
Exome and RNA Sequencing
50-500 ng DNAwas sequenced at the Tumor Profiling Unit, ICR, London, UK using the SureSelect Human All Exon capture sets V4 or
V5 (Agilent, Santa Clara, CA, USA), and paired-end-sequenced on an Illumina HiSeq2000 (Illumina, San Diego, CA, USA) with a
100 bp read length. Coverage ranged from 29-295x (median=105x). RNA was sequenced at the ICR Tumor Profiling Unit after
SureSelect RNA capture on an Illumina HiSeq2500 with a 125 bp read length.
QUANTIFICATION AND STATISTICAL ANALYSIS
Published Data Sources
These data were combined with those obtained directly from the authors or from public data repositories representing 20 published
studies (Barrow et al., 2011; Bax et al., 2010; Buczkowicz et al., 2014; Carvalho et al., 2014; Castel et al., 2015; Fontebasso et al.,
2013, 2014; Grasso et al., 2015; International Cancer Genome Consortium PedBrain Tumor Project, 2016; Khuong-Quang et al.,
2012; Korshunov et al., 2015; Paugh et al., 2010, 2011; Puget et al., 2012; Schwartzentruber et al., 2012; Sturm et al., 2012; Taylor
et al., 2014a; Wu et al., 2012; Wu et al., 2014; Zarghooni et al., 2010) with the following accession numbers: EGA -
EGAS00001000226, EGAS0000100192, EGAS00001000575, EGAS00001000720, EGAS00001001139; the Gene Expression
Omnibus (www.ncbi.nlm.nih.gov/geo/) - GSE19578, GSE26576, GSE21420, GSE34824, GSE36245, GSE36278 GSE50022,
GSE50021, GSE50024, GSE55712; ArrayExpress - E-TABM-857 , E-TABM-1107 . The full cohort included a total of 1254 molecular
profiles from 955 samples across 12 platforms, which after quality control and manual annotation to remove duplicates, and supple-
mentedwith targeted sequencing of an additional 158 cases, resulted in a total dataset comprised of 1067 individual patients. The full
dataset comprises genomic profiles from DNA copy number arrays (Agilent 44K, n=127; Affymetrix 500K, n=100; Affymetrix SNP6.0,
n=78; 32k BAC, n=61), Illumina 450k methylation arrays (n=441), whole exome (n=254), genome (n=125), targeted (n=212) and RNA
sequencing (n=82), as well as gene expression from Affymetrix U133Plus2 (n=102) and Agilent WG2.5 (n=67) platforms.
DNA Copy Number
DNA copy number data was obtained as array CGH (Agilent 44k and 32K BAC), SNP arrays (Affymetrix 500k and SNP6.0), 450k
methylation arrays (Illumina) and/or sequencing data (whole genome and exome). Two color aCGH data was read and normalized
using the R packages limma and marray. Log intensity data from Affymetrix SNP arrays was derived using the aroma.affymetrix
and aroma.cn package. Combined log2 intensity data from Illumina 450K methylation arrays was processed using the R packages
minfi and conumee. For sequenced samples, coverage of aligned reads was binned into known genes and exons with BEDTools ande3 Cancer Cell 32, 520–537.e1–e5, October 9, 2017
log2 ratios of median coverage in tumor and normal sequences were processed with in-house scripts. To combine copy number plat-
forms, median log2 ratios were recovered within all known genes and exons and normalized such that the median displacement of X
in male:female comparisons was rescaled to an average of -1. Exon-level median log ratios and smoothed values were then com-
bined across platforms and thresholded to call gains and losses above and below log2 ratios of ±0.3 with a contig of 1MB and
amplifications and deletions above and below a threshold of ±1.5 with a minimum of 3 contiguous exons.
CBS binary segmentation from the DNAcopy package was applied to each dataset to provide smoothed log2 ratios. Genes within
common CNVs in normal individuals were excluded from further analysis with reference to the CNVmap of the human genome. DNA
copy number data was clustered based upon categorical states (deep deletion, loss, no change, gain and amplification) based upon
the Euclidean distance method with a Ward algorithm. Gains and losses in chromosomal arms were called based upon contiguous
regions covering more than one third of the exonic regions within each arm. For regions of focal copy number change cases carrying
copy number alterations were ranked according to the length of the largest CNA in each case and are plotted as heatmaps aligned to
precise genomic coordinates alongside genomic tracks based upon hg19 made with the R package gviz. Minimal regions of copy
number alteration were assigned based on the frequency of categorical states within each region. Focal amplifications and deletions
were identified in CBS segmented data using the GISTIC algorithm in MATLAB on the exon-level data, with thresholds for gain and
loss of 0.3 and gene-level filters to remove regions of common copy number variation in normal individuals based on the CNVmap of
the human genome.
DNA Methylation
Methylation data from the Illumina Infinium HumanMethylation450 BeadChip was preprocessed using the minfi package in R. DNA
copy number was recovered from combined intensities using the conumee package with reference to methylation profiles from
normal individuals provided in the CopyNumber450kData package. We have used the Heidelberg brain tumor classifier
(molecularneuropathology.org) to assign subtype scores for each tumor compared to 91 different brain tumor entities using a training
set built from more than 2000 tumors implemented in the MNP R package. Simplified methylation subgroup assignments were then
made to incorporate cases carrying G34R/V or K27Mmutations in H3 histones, IDH1mutation at R132, low grade glioma-like profiles
(predominantly diffuse infantile ganglioglioma and pilocytic astrocytoma) and those similar to pleomorphic xanthoastrocytoma (PXA).
Wild-type HGG encompassed many other methylation subgroups and were simply assigned by exclusion with the groups above.
Clustering of beta values from methylation arrays was performed using the 10K probeset from the Heidelberg classifier based
upon Euclidean distance with a ward algorithm. Methylation heatmaps show only the most variable probes of the classifier between
simplified methylation subgroups. Overall methylation was calculated as the mean of the 10K classifier probeset for each subgroup
and MGMT promoter methylation was calculated based upon the MGMT-SPT27 model implemented in the MNP package. t- sto-
chastic neighbor embedding (tSNE) was used to project the methylation clustering in three dimensions using the Rtsne package.
A Pearson correlation matrix of the 10K probeset was subjected to tSNE using a theta value of zero over 10,000 iterations as previ-
ously described and plotted using the rgl package.
mRNA Expression
Gene expression data was obtained from Agilent WG2.5, Affymetrix U133Plus2.0 or RNA sequencing platforms. Gene expression
was processed from two color Agilent microarrays using the R packagesmarray and limma and from single channel Affymetrix arrays
using the affy package. Differential expression was assigned for microarray data using the limma package based upon a false dis-
covery rate of 5%. RNASeq was aligned with Bowtie2 and TopHat and summarized as gene level fragments per kilobase per million
reads sequenced using BEDTools and cufflinks/cuffnorm. Following rlog transformation and normalization, differential expression
was assigned with DESeq.2. Known Ensembl genes were further filtered to remove low abundance genes in all three datasets whose
maximal expression was within the lowest 20% of all expression values based upon probe intensities or read depth. Replicate
probes/features for each gene were removed by selecting those with the greatest median absolute deviation (MAD) in each dataset.
Following centering within each dataset, log-transformed expression measures were combined and further normalized using pair-
wise loess normalization. Gene Set Enrichment Analysis was performed using the GSEA java application based upon pairwise com-
parisons of the major subgroups in the merged dataset. Heatmaps of gene expression across chromosomal arms were made using
centered expression values rescaled across each chromosomal arm based upon the median absolute deviation of each probe. Dif-
ferential expression analysis of TOP3A and FBXW7 was based on a Mann-Whitney U test of centred expression values between
cases with and without losses and amplifications respectively in each case.
Sequence Analysis
Sequencing data was available as whole genome and/or whole exome (predominantly using Agilent’s SureSelect whole exome cap-
ture sets v4 and v5) Short read sequences fromwhole exome or whole genome sequencing were aligned to the hg19 assembly of the
human genome using bwa. Following duplicate removal with Picard tools variants were called using the Genome Analysis toolkit
according to standard Best Practices (Broad) including local re-alignment around Indels, downsampling and variant calling with
the Unified Genotyper. Variants were annotated with the variant Effect predictor v74 from Ensembl tools and ANNOVAR to include
annotations for variant allele frequency in 1000 genomes dbSNP v132 and the ExAc database as well as functional annotation tools
SIFT andPolyphen). Depth of coverage varied from16-295x (median 88x), with the greatest variation unsurprisingly in the exomedata
(whole genome range 50-150x, median=85x). Somatic variants were identified in regions covered by at least 10 reads in normal andCancer Cell 32, 520–537.e1–e5, October 9, 2017 e4
tumor sequences carrying at least 3 variant reads in the tumor and less than 2 in normal sequences. Hotspot TERT promoter muta-
tions C228T and C250Twere incidentally captured by the various exome platforms as they are located only 114 and 146 bp upstream
of the translation start site, and were called even if only covered by a few reads. Mutation signatures were ascertained by grouping
somatic substitutions on the basis of their 30 and 50 bases into 96 possible trinucleotide categories.
Candidate Fusion Gene Nomination
Structural variants were called from whole genome data using Breakdancer (breakdancer.sourceforge.net) filtered to remove
commonly multi-mapped regions to identify somatic breakpoints separated by a minimum of 10 kbp involving at least one Ensembl
gene. Fusion transcripts were detected from RNAseq data using chimerascan version 0.4.5a filtered to remove common false pos-
itives. To minimize unverified false positives, reporting of nominated fusions was restricted to genes within the core functional path-
ways and processes identified through integrated DNA copy number and somatic variant calling.
Inferred Tumor Purity
Weused determined the somatic allele-specific copy number profiles using read depth fromwhole genome / exome sequencing, and
used ASCAT (rick.ac.uk/peter-van-loo/software/ASCAT) to provide for an estimate of the non-neoplastic cell contamination of the
sample as well as the overall ploidy of the tumor. Values ranged from 36-100%, with a median of 83%.
Integrated Analysis of Driver Events
Somatic non-synonymous coding mutations were filtered to remove common passenger mutations, polymorphisms and false pos-
itives in exome sequencing. Data were integrated with focal DNA copy number calls by GISTIC to provide gene-level binary alteration
calls which were further selected for putative drive status on the basis of functional annotation. Oncoprint representations of inte-
grated mutations, gene-level copy number alterations and fusion events were made using the online tool available at cBioportal
(cbioportal.org). For the most commonly mutated genes mutations were mapped to the canonical transcript and plotted according
to their predicted protein position using the Protein Painter (pecan.stjude.org). Integrated views of copy number alterations, structural
variants and somatic mutations were made using CIRCOS (circos.ca) and rearrangements within TOP3A amplified regions in whole
genome sequenced cases were identified using Breakdancer and aligned with copy number breakpoints in R.
Pathway Analysis
Pathway assignments weremade for all genes carrying copy number alterations, structural variations or somatic mutations based on
pathways in theMSigDBmolecular signatures databases (Broad) as well as Gene Ontologies for Biological Processes andMolecular
Functions (Gene Ontology consortium) and canonical pathways from KEGG, NetPath and Reactome. Genes within known CNVs and
common false positives in exomic sequencing were excluded with reference to large scale genome profiling studies (CNVmap, ExAc,
BCBio) Pathway analysis of genes carrying mutations, gene fusions and copy number aberrations was based on the pathways
defined by these combined databases and subjected to enrichment analysis using the EnrichmentMap module within CytoScape.
Statistical Analysis
Statistical analysis was carried out using R 3.3.1 (www.r-project.org). Categorical comparisons of counts were carried out using
Fishers exact test, comparisons between groups of continuous variables employed Student’s t-test, Wilcoxon signed –rank test,
ANOVA or Mann-Whitney U test. Differences in survival were analysed by the Kaplan-Meier method and significance determined
by the log-rank test. All tests were two-sided and a p value of less than 0.05 was considered significant. Multiple testing was ac-
counted for using false discovery rate q values or the Bonferroni adjustment.
DATA AND SOFTWARE AVAILABILITY
All newly generated data have been deposited in the EuropeanGenome-phenome Archive (www.ebi.ac.uk/ega) with accession num-
ber EGAS00001002314 (sequencing) or ArrayExpress (www.ebi.ac.uk/arrayexpress/) with accession number E-MTAB-5528 (450k
methylation).
ADDITIONAL RESOURCES
Processed copy number profiles are hosted as a disease-specific project within the Progenetix framework for annotated genomic
analyses (dipg.progenetix.org) (Cai et al., 2014), and represented in the arrayMap resource (arraymap.org) (Cai et al., 2012). Curated
gene-level copy number and mutation data are provided as part of the pediatric-specific implementation of the cBioPortal genomic
data visualisation portal (pedcbioportal.org). Newly-generated raw data files are housed alongside published datasets made avail-
able to the Cavatica NIH-integrated cloud platform (www.cavatica.org).e5 Cancer Cell 32, 520–537.e1–e5, October 9, 2017
